Community-acquired pneumonia (CAP) is a major health problem in the United States and
is associated with substantial morbidity, mortality, and health care costs. Patients with CAP …

The overwhelming majority of cases of community-acquired pneumonia (CAP) can be
treated with the standard antibiotic regimens of a macrolide and cephalosporin or a …

Background Pneumonia is a relevant clinical and public health issue worldwide frequently
associated with infections caused by Multi-Drug Resistant (MDR) pathogens. Ceftaroline …

Ceftaroline fosamil is a cephalosporin antibacterial approved by the US Food and Drug
Administration (FDA) for use in the treatment of acute bacterial skin and skin structure …

Community-acquired pneumonia (CAP) is a common infectious disease in the United States
and the incidence continues to grow as the aging population increases. Overall, in-hospital …

Ceftaroline is a fifth-generation cephalosporin with potent antimicrobial activity against Gram-
positive and Gram-negative pathogens. Neutropenia is a rare serious adverse event for the …

Intestinal dysbiosis increases susceptibility to infection through the alteration of metabolic
profiles, which increases morbidity. Zinc (Zn) homeostasis in mammals is tightly regulated by …

Ceftaroline fosamil is a parenteral cephalosporin indicated for the treatment of acute
bacterial skin and skin structure infections and community‐acquired bacterial pneumonia …

Objective: To summarize published data regarding the use of ceftaroline as salvage
monotherapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia …

Objectives Ceftaroline fosamil, the prodrug of the active metabolite ceftaroline, is a broad-
spectrum, parenteral cephalosporin approved for treatment of moderate to severe bacterial …